- About us
- Clinical trials
- News & Publications
September 4, 2013
On Thursday, September 12th, Sotio will be joining forces with esteemed Massachusetts state legislators, patient advocacy groups, and local Boston athletes in an effort to urge legislators to recognize prostate cancer as a public health priority. Sponsored since 2009 by the AdMeTech Foundation, the event will also include discussions on recent advances in the diagnosis and treatment of prostate cancer and a measure to increase funding to the National Institute of Health for the advancement of early detection initiatives.
Sotio is a biotechnology company that is developing a next generation Active Cellular Immunotherapy (ACI), based on activated dendritic cells for the treatment of cancer and autoimmune diseases. Sotio plans to launch a global Phase 3 clinical trial in 2013 to assess the safety and efficacy of its investigational therapy, DCVAC/PCa, in combination with 1st line standard of care chemotherapy in men with metastatic castration resistant Prostate Cancer. Please show your support and join us at the State House in Boston on September 12th from 10am-1pm. Register at http://www.admetech.org/ or by phone at 617.523.3535